EUVIMEDEUVIMED entdecken
Crossref

Disease Outcomes in Immune-Mediated Colitis: A Study Describing Initial Endoscopic and Histologic Presentations and Treatment Options

Malek Shatila, Carolina Colli Cruz, Kei Takigawa, Andres Caleb Urias Rivera, Kian Abdul-Baki, Tanvi Gupta, Elliot Baerman, Linfeng Lu, Irene Jeong-Ah Lee, Raakhi Menon, Andrew Sullivan, Varun Vemulapalli und 9 weitere

Journal of the National Comprehensive Cancer Network · 2025

DOI: 10.6004/jnccn.2025.7046 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2025. Verfasst von Malek Shatila und 20 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston TX. Hauptthemen laut MEDLINE: Colitis, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Immune-mediated colitis (IMC) is a toxicity associated with immune checkpoint inhibitors (ICIs) that is becoming increasingly common. Studies exploring the clinical course and outcomes of IMC have been limited to relatively small sample sizes (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ColitisImmune Checkpoint InhibitorsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedAdultTreatment OutcomeColonoscopyImmunosuppressive AgentsAged, 80 and over

Substanzen

Immune Checkpoint InhibitorsImmunosuppressive Agents

Autor:innen und Institutionen

  • 1Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston TX.
  • 2Department of Internal Medicine, Baylor College of Medicine, Houston, TX.
  • 3Department of Internal Medicine, The University of Texas Medical Branch, Galveston, TX.
  • 4Department of Internal Medicine, The University of Texas Health Sciences Center, Houston, TX.
  • 5The Memorial Hermann Texas Medical Center, Houston, TX.
  • 6Division of Hematology and Oncology, Vanderbilt University, Nashville, TN.

Zitieren

APA

Shatila, M., Cruz, C. C., Takigawa, K., Urias Rivera, A. C., Abdul-Baki, K., Gupta, T., Baerman, E., Lu, L., Lee, I. J., Menon, R., Sullivan, A., Vemulapalli, V., Natha, C., Salim, H., Khan, A., Varatharajalu, K., Johnson, D., Kim, K., Champiat, S., …, & Wang, Y. (2025). Disease Outcomes in Immune-Mediated Colitis: A Study Describing Initial Endoscopic and Histologic Presentations and Treatment Options. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2025.7046

Vancouver

Shatila M, Cruz CC, Takigawa K, Urias Rivera AC, Abdul-Baki K, Gupta T, et al. Disease Outcomes in Immune-Mediated Colitis: A Study Describing Initial Endoscopic and Histologic Presentations and Treatment Options. Journal of the National Comprehensive Cancer Network. 2025. doi:10.6004/jnccn.2025.7046

BibTeX
@article{Shatila2025,
  author = {Shatila, Malek and Cruz, Carolina Colli and Takigawa, Kei and Urias Rivera, Andres Caleb and Abdul-Baki, Kian and Gupta, Tanvi and Baerman, Elliot and Lu, Linfeng and Lee, Irene Jeong-Ah and Menon, Raakhi and Sullivan, Andrew and Vemulapalli, Varun and Natha, Cristina and Salim, Hamza and Khan, Ayesha and Varatharajalu, Krishnavathana and Johnson, Douglas and Kim, Karen and Champiat, Stephane and Thomas, Anusha Shirwaiker and Wang, Yinghong},
  title = {Disease Outcomes in Immune-Mediated Colitis: A Study Describing Initial Endoscopic and Histologic Presentations and Treatment Options},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2025},
  doi = {10.6004/jnccn.2025.7046}
}
Kostenlos starten →